Login to Your Account

Genticel Gets $24M for Therapeutic HPV Vaccine

By Cormac Sheridan
Staff Writer

Friday, April 26, 2013
Genticel SA raised €18.2 million (US$23.6 million) in a Series C round led by Wellington Partners, to move ProCervix, its bivalent therapeutic vaccine for combating human papillomavirus (HPV) infection into Phase II trials.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription